Log In
Friday 25th May 2018

Domantis sold to GSK

12th December 2006

Cambridge based Domantis has just been sold to GlaxoSmithKline for £230m.

Ian Tomlinson and Sir Gregory Winter, who founded the company six years ago, are set to make £15m each from the deal which was finalised on Monday.

Ian Tomlinson studied at Trinity College, Cambridge and took a PhD in antibodies before moving on to the Medical Research Council Laboratory of Molecular Biology (LMB), where he headed up his own research team.  Sir Gregory Winter is a renowned expert in the field of antibody engineering and developed a unique way of producing antibodies without the need for animals. 

Domantis was formed out of the LMB, the same laboratory that produced Cambridge Antibody Technology (CAT), the biotechnology company that was sold to GlaxoSmithKline's rival, AstraZeneca, this year for £702m.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Article Information

Title: Domantis sold to GSK
Article Id: 1464
Date Added: 12th Dec 2006


The Financial Times

Recent Related Articles

Energy drinks ban in the UK


Add to scrapbook
Show Comments
Add comment
Find all related articles


Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2018